TheraRadar
Home/Indications/Lower Respiratory Tract Infection

Lower Respiratory Tract Infection

0 original drugs
0
Novel Drugs
11
Reformulations
0
Active Trials
1
Drug Targets

Phase 3 Readouts Pro

9 active Phase 3 trials with confidence-graded completion dates.

Full calendar →
Q4 2026
Pirfenidone Capsules (400 mg)
Beijing Continent Pharmaceutical Co, Ltd.
Estimated · fresh NCT07388680
Q4 2026
Meropenem and Pralurbactam
Qilu Pharmaceutical Co., Ltd.
Estimated · aging NCT07089186
Q4 2027
BV100 (300 mg)
BioVersys SAS
Estimated · fresh NCT07326540
Unlock 6 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 4 mechanisms across 7 industry trials with a known mechanism of action.

See full pipeline →
Tetracycline-class Antibacterial
3 trials 2 sponsors
Fluoroquinolone Antibacterial
2 trials 2 sponsors
Interleukin-1 Receptor Antagonist
1 trials 1 sponsor
Interleukin-6 Antagonist
1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

226 industry-sponsored trials across 123 sponsors

Novel Drugs by Company (New molecular entities)

No novel drugs found for this indication.

Reformulations (11 drugs) Click to expand
Generic Drugs (17 ANDA approved) Click to expand

Drug Categories:

  • Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
  • Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
  • Biosimilars: BLA-approved biologics highly similar to reference products
  • Generics: ANDA-approved copies of small molecule drugs

View data sources and methodology